Your vital support means we’re able to rapidly adapt our pioneering research so that the search for better treatments and a cure continues. Your fundraising will help support our trailblazing science, when it comes to finding a cure, impatience is a virtue.
Your mum, son or friend. Anyone can get Parkinson’s, young or old. Every hour, two more people are diagnosed. Parkinson’s UK estimates that around 145,000 people live with a Parkinson’s diagnosis in the UK in 2020. With population growth and ageing, we estimate that this will increase by a fifth, to around 172,000 people in the UK, by 2030. Find out about Genna’s story here. ‘It’s hard to juggle it all and manage everything’
JOIN TEAM PARKINSONS
Join our team at the Brighton Marathon Weekend and together we can make a stand and play our part – fighting for fair treatment and better services. Making everyone see its real impact. Sign up today!
But we know we’re close to major breakthroughs. By funding the right research into the most promising treatments, we get closer to a cure every day. Until then, we’re here for everyone affected by Parkinson’s.
People with Parkinson’s urgently need new treatments. But right now, there’s a huge gap in drug development. That’s why we set up our Virtual Biotech, fast tracking the most promising scientific discoveries into life-changing new treatments.
There’s no shortage of exciting research discoveries happening. And pharmaceutical companies are ready to fund large-scale trials and get new drugs to market at the other end. But the middle stage, taking promising research and developing it into potential drug treatments? That’s where we see a critical funding shortage.
So at Parkinson’s UK, we’re stepping up to fund that gap. And we’re not doing it alone. We’re a powerful global movement of scientists and supporters, investors and innovators. Driven by people with Parkinson’s every step of the way.
What’s a biotech? It’s a company using biological research to make treatments. Our Virtual Biotech is a little different. Unlike a traditional biotech, none of our funding is tied up in bricks or people. We have no large teams of scientists or expensive labs to run.
We take an agile approach. Partnering with institutions and pharmaceutical companies worldwide that already have the expertise, tools and infrastructure. Fast tracking the projects with the greatest potential to transform life for people with Parkinson’s.
No one else is doing this. We’re taking bold risks. And we’re pushing for a ground breaking new treatment by the end of 2024.